Disclosed are compounds having the formula (I): ##STR00001## including compounds of formulae (Ia) and (Ib): ##STR00002## wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR.sup.7R.sup.7' or NR.sup.10, and M' is a bond or NR.sup.10, with the proviso that at least one of M or M' must be a bond; E is C=Z.sub.2, CR.sup.7CR.sup.7', SO.sub.2, P.dbd.OR.sup.2, or P.dbd.OOR.sup.2; Z.sub.1 is O, S, NH, or NR.sup.6; A.sub.1 is CR.sup.7 or N; A.sub.2 is CR.sup.7 or N; Y is J-J'-J'' where J is (CR.sup.7R.sup.7')n and n=0-3, J' is a bond or O, S, S.dbd.O, SO.sub.2, NH, NR.sup.6, C.dbd.O, CO.dbd.O, NR.sup.1C.dbd.O, CR.sup.7R.sup.7', C.dbd.CR.sup.8R.sup.8', R.sup.2P.dbd.O, OPOOR.sup.2, OPO.sub.2, OSO.sub.2, C.dbd.N, NHNH, NHNR.sup.6, NR.sup.6NH, N.dbd.N, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo or aryl or substituted aryl, and J'' is (CR.sup.7R.sup.7')n and n=0-3; and W, Q, R.sup.2, R.sup.6, R.sup.7, R.sup.7', R.sup.8, R.sup.8', R.sup.9, R.sup.9', and R.sup.10 are as defined in the specification and/or claims herein, to methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and to pharmaceutical compositions containing such compounds.